Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.5K
Overview
51.5K
Cancer Vaccines01:30

Cancer Vaccines

1.0K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.0K
Tumor Progression02:07

Tumor Progression

7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
The Nucleolus02:55

The Nucleolus

10.3K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.3K
Reaction Rate02:53

Reaction Rate

62.6K
The rate of reaction is the change in the amount of a reactant or product per unit time. Reaction rates are therefore determined by measuring the time dependence of some property that can be related to reactant or product amounts. Rates of reactions that consume or produce gaseous substances, for example, are conveniently determined by measuring changes in volume or pressure.
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
62.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel multiplex approach for the comprehensive analysis of the Epstein-Barr virus-specific humoral immune response.

Frontiers in cellular and infection microbiology·2026
Same author

The composition of MDSC-subpopulations PMN-like, M-like, and e-like MDSC is associated with the severity of infectious mononucleosis in pediatric patients.

Frontiers in immunology·2026
Same author

Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Strains.

Current topics in microbiology and immunology·2026
Same author

Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.

Blood neoplasia·2026
Same author

Guiding Antiviral Cell Therapy Approaches with an Online Resource of Clinically Scored Epitopes, T-Cell Receptors, and B-Cell Receptors.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2025
Same author

Exploratory study on autoantibodies to arginine-rich human peptides mimicking Epstein-Barr virus in women with post-COVID and myalgic encephalomyelitis/chronic fatigue syndrome.

Frontiers in immunology·2025

Related Experiment Video

Updated: Jan 28, 2026

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
09:37

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique

Published on: September 23, 2022

2.2K

Progress in EBV Vaccines.

Dwain G van Zyl1,2,3, Josef Mautner3,4, Henri-Jacques Delecluse1,2,3

  • 1German Cancer Research Center (DKFZ), Heidelberg, Germany.

Frontiers in Oncology
|March 13, 2019
PubMed
Summary

Developing effective Epstein-Barr virus (EBV) vaccines remains a challenge. Novel vaccine candidates show promise in preventing EBV infection and associated diseases like mononucleosis and cancers.

Keywords:
EBV (Epstein-Barr virus)lympho proliferative disorderoncogenicvaccineγ-herpesvirus

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K

Related Experiment Videos

Last Updated: Jan 28, 2026

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
09:37

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique

Published on: September 23, 2022

2.2K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Epstein-Barr virus (EBV) is a widespread pathogen causing infectious mononucleosis, cancers, and autoimmune diseases like multiple sclerosis.
  • Despite extensive research, no licensed EBV vaccine is currently available.
  • Previous vaccine efforts focused on the gp350 protein, showing limited success in preventing infection.

Purpose of the Study:

  • To review the current landscape of EBV vaccine development.
  • To highlight the limitations of previous vaccine strategies.
  • To introduce novel vaccine candidates with enhanced complexity and antigenicity.

Main Methods:

  • Review of existing literature on EBV vaccines.
  • Analysis of clinical trial data for gp350-based vaccines.
  • Discussion of emerging vaccine technologies and targets.

Main Results:

  • The gp350 vaccine candidate reduced infectious mononucleosis incidence but did not prevent EBV infection.
  • Novel vaccine candidates incorporate increased structural complexity and antigenic content.
  • Next-generation vaccines aim to protect against B-cell and epithelial cell infection and target infected cells across all infection phases.

Conclusions:

  • Current EBV vaccine development faces significant hurdles.
  • Novel vaccine strategies offer improved prospects for controlling EBV infection and associated diseases.
  • Advanced vaccine designs hold the potential to mitigate the global health burden of EBV.